Prader–Willi syndrome: Symptoms and topiramate response in light of genetics
- 1Centre de Référence pour les Maladies Rares à expression Psychiatrique, GHU Paris Psychiatrie et Neurosciences, Paris, France
- 2Department of Child and Adolescent Psychiatry, Pitié-Salpêtrière Hospital, Paris, France
- 3GRC-15, Dimensional Approach of Child and Adolescent Psychotic Episodes, Faculté de Médecine, Sorbonne Université, Paris, France
- 4Nutrition Department, Rare Diseases Center of Reference “Prader–Willi Syndrome and Obesity With Eating Disorders” (PRADORT), Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière Hospital, INSERM, Nutriomics, Sorbonne Université, Paris, France
- 5Institute of Psychiatry and Neuroscience of Paris (IPNP), INSERM U1266, Université Paris Cité, Paris, France
- 6Department of Psychiatry, McGill University, Montréal, QC, Canada
A corrigendum on
Prader-Willi syndrome: Symptoms and topiramate response in light of genetics
by Louveau, C., Turtulici, M.-C., Consoli, A., Poitou, C., Coupaye, M., Krebs, M.-O., Chaumette, B., and Iftimovici, A. (2023). Front. Neurosci. 17:1126970. doi: 10.3389/fnins.2023.1126970
In the published article, an author name was incorrectly written as Turtuluci. The correct spelling is Turtulici.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: Prader–Willi, topiramate, treatment, genetics, deletion, disomy, personalized medicine
Citation: Louveau C, Turtulici M-C, Consoli A, Poitou C, Coupaye M, Krebs M-O, Chaumette B and Iftimovici A (2023) Corrigendum: Prader-Willi syndrome: Symptoms and topiramate response in light of genetics. Front. Neurosci. 17:1189154. doi: 10.3389/fnins.2023.1189154
Received: 18 March 2023; Accepted: 20 March 2023;
Published: 31 March 2023.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2023 Louveau, Turtulici, Consoli, Poitou, Coupaye, Krebs, Chaumette and Iftimovici. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Cécile Louveau, cecile.louveau@ghu-paris.fr; Anton Iftimovici, anton.iftimovici@inserm.fr